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Abstract
Purpose Our aim was to summarize key aspects of
the pathomechanism and the ocular involvements of
rheumatic and systemic autoimmune diseases.
Methods Apart from a paper in French (Morax V,
Ann Oculist 109:368–370, 1893), all papers referred to
in this article were published in English. All the
materials were peer-reviewed full-text papers, letters,
reviews, or book chapters obtained through a literature
search of the PubMed database using the keywords
ocular manifestations; pathogenesis; systemic inflam-
matory rheumatic diseases; rheumatoid arthritis;
osteoarthritis; fibromyalgia; systemic lupus erythe-
matosus; seronegative spondyloarthritis; ankylosing
spondylitis; reactive arthritis; enteropathic arthritis;
psoriatic arthritis; systemic sclerosis; polymyalgia
rheumatica and covering all years available. Some
statements articulated in this paper reflect the clinical
experience of the authors in their tertiary-referral
center.
Results Ophthalmic disorders are categorized by
anatomical subgroups in all rheumatic diseases. The
most common ocular manifestations are diverse types
of inflammations of different tissues and dry eye
disease (DED).
Conclusion The eye could be a responsive marker
for the onset or aggravation of an immune reactivation
in many rheumatic diseases, furthermore, ocular
findings can antedate the diagnosis of the underlying
rheumatic disease. By recognizing ocular manifesta-
tions of systemic rheumatic diseases it might be
possible to avoid or at least delay many long term
sequelae.
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Introduction
Most of the inflammatory rheumatic diseases are
systemic conditions with several clinical and patho-
logical manifestations outside of the joints. The eye
has a distinguished innate and adaptive immune
system underpinned by even the presence of the
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blood–retina barrier and the alymphatic status of its
inner structure. The liquid components of the eye,
namely the aqueous and vitreous humors, are sepa-
rated from the blood by tight junctions (occluding
junctions or zonulae occludentes) [1], which con-
tribute to maintaining the ideal microenvironment of
the eyeball. Inflammatory rheumatic diseases can have
destructive effects since as a consequence of vascular
abnormality immunoregulatory molecules present in
ocular fluids are changed and milieu interieur inside
the eye is modulated.
Not only ophthalmologically may the identification
of ocular signs and symptoms be of importance, but
ocular inflammation could also be a sensitive marker
for the severity of the systemic condition; moreover,
ocular involvement can antedate exacerbation of an
immune reaction in many systemic diseases. Hence,
knowledge of ocular manifestations of rheumatic
diseases is indispensable for both rheumatologists
and immunologists. This review article intends to
resume the key pathogenic events, as well as to depict
ophthalmologic manifestations of rheumatic diseases.
Rheumatoid arthritis (RA)
RA is a chronic autoimmune inflammatory disease of
unknown origin marked by joint swelling, joint
tenderness, and destruction of synovial joints, result-
ing in severe disability and premature mortality [2].
Concerning ocular manifestations of RA, we have to
lay down that the anterior segment is more commonly
affected compared to the posterior segment.
Cornea
A wide range of corneal manifestations can occur in
RA. Corneal involvement can be definitely sight-
threatening mainly in case of an overlying infection.
Aggressive intravenous antibiotics should be consid-
ered in addition to local eye drops in the case of
patients on biologic agents for corneal ulcer [3].
Episcleritis/scleritis/uveitis
Episcleritis (Fig. 1) and scleritis can be manifestations
of RA and vice versa the etiology of these alterations is
often a connective tissue disease, and RA is the
commonest. When the clinical data of a large
population presenting with uveitis and/or scleritis
were reviewed, the origin of these ocular complica-
tions was found to be 5% autoimmune, 15% auto-
inflammatory and 14% mixed autoimmune/auto-in-
flammatory. The term ‘‘autoimmune uveitis’’ [4]
should not be used as a synonym for intraocular
inflammation of non-infectious origin, just be reserved
for intraocular inflammations of confirmed autoim-
mune origin. Anti-cyclic citrullinated (anti-CCP)
peptide is an important diagnostic and prognostic tool
for RA, since out of all laboratory parameters, the level
of this antibody was significantly associated with
ocular manifestations in RA [5].
Dry eye disease (DED)
Is there ever such a great variability in the prevalence
of lacrimal gland involvement in RA, DED can surely
be regarded as its most common ocular involvement
often noticed in patients when the underlying disease
is associated with Sjo¨gren’s syndrome (SS). The
analysis of the data of 143 consecutive RA patients
found that 45% of them had subjective symptoms and
38% had objective signs of DED [6]. As for gender
characteristics of DED in RA, women are 9 times
more commonly affected than men [7].
Choroid
Kurt et al. demonstrated decreased corneal thickness
(CT) of 59 RA patients compared to healthy controls.
However, no significant correlation was found
Fig. 1 Extensive episcleritis with dilated blood vessels at the
temporal region in an RA patient
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between CT measurements and Disease Activity Score
28 (DAS 28) or Larsen disease activity scores [8].
Osteoarthritis (OA)
By definition, OA or degenerative arthritis is a
complex condition characterized by focal areas of
loss of articular cartilage within the synovial joints,
associated with simultaneous hypertrophy of the bone
and thickening of the capsule, resulting in substantial
pain and disability.
Retina
Age-related macular degeneration (AMD) is the major
cause of blindness in developed countries [9]. AMD is
strongly associated with aging; there is extreme
involvement of the extracellular matrix in its patho-
physiology and implication of the complement path-
way of the innate immune system [10]. A survey of the
epidemiologic relationship between AMD and OA
patients found that AMD patients did not have a higher
risk for OA formation, while a modestly increased risk
for the appearance of neovascular AMD was noticed
in patients with OA as well as RA perhaps due to
medical treatments for the underlying disease [11].
Fibromyalgia (FM)
FM is a complex condition with widespread chronic
musculoskeletal pain, which is accompanied by a
range of other symptoms including fatigue, poor sleep,
memory issues, and depression [12].
FM independently or together with depression and
neuroticism contributes to the development of primary
SS-associated fatigue, and therefore DED could be
mentioned as its elementary ocular sign [13].
Concerning its further ocular manifestations, a case
report was presented by Tenkman et al. of a fifty-plus
female with definite keratoconus (KC)—an ectatic
disorder of the cornea which produces progressive
thinning—in the one eye and a possible KC in the
fellow eye [14]. The patient was without a family
history of KC or any connective tissue disease for that
matter other than FM [15].
Systemic lupus erythematosus (SLE) or lupus
SLE or simply lupus is a highly heterogeneous chronic
autoimmune disease with undefined etiology in which
the body’s immune system mistakenly attacks healthy
tissues [16]. It is predominantly women, who can be
affected in their childbearing age.
Orbital involvement
Extraocular muscles can be inflamed, and even
inflammatory pseudotumor can develop, the diagnosis
of which can be delayed by reason of simultaneous
immunosuppressive and low dose oral corticosteroid
therapy [17]. An uncommon clinical presence in the
SLE spectrum is panniculitis, also called lupus
erythematosus profundus which is presented in a case
report as masked by an accompanying idiopathic
orbital inflammatory syndrome (IOIS), a nonspecific
inflammation of orbital tissue, which is typically
manifest in SLE.
Eyelid
In SLE, typically in lower eyelids, a specific, irritating,
discrete, slightly raised erythematous scaly plaque
called discoid lupus-type rash can appear, which may
be complicated by scar formation, scaling and
madarosis, or sometimes dyspigmentation [18]. Topi-
cal corticosteroids and oral antimalarial drugs can be
administered in these cases.
Cornea and DED
DED is the most frequent ocular manifestation of SLE
occurring in one-third of patients because of the
involvement of both the main and the accessory
lacrimal glands [19]. Besides DED, a wide range of
corneal alterations can be found ranging from super-
ficial punctate keratitis through stromal infiltration to
peripheral ulcerative keratitis [18].
Episcleritis and scleritis
Episcleritis and scleritis may be identified as unusual
involvements in SLE; nevertheless, they can be
predictive signs of an active status. Both of them can
be initial findings followed by other ocular manifes-
tations in SLE, especially in the case of the latter,
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which is often underdiagnosed although it may be
more severe with enduring visual impairment [20].
Retinal and choroidal changes
The prevalence of retinal abnormalities ranges from 3
to 29% depending on the examined population and the
disease stage; the previous value represents the well-
controlled patients, while the latter is attributed to
patients with a more active underlying disease.
Mostly, central arterial occlusions can be seen, but
there are several cases describing combined central
retinal artery and vein occlusion even in a bilateral
form [21]. An unusual form of retinal vascular
alterations is the Purtscher’s retinopathy, the patho-
genesis of which is based on embolic occlusions of the
precapillary arterioles caused by increased intracra-
nial/intrathoracic pressure and secondary extravasa-
tion of fluid [22]. Choroidopathy is less frequent
compared to retinopathy and can be detected by
indocyanine green angiography (ICG-A). This diag-
nostic tool could be useful in the screening of patients
with SLE to decide whether to perform a renal biopsy
or not since, according to a study, the deformations of
choroidopathy by ICG-A could be an indirect sign of
renal involvement [23].
Seronegative spondyloarthritis or seronegative
spondylarthropathies (SpA)
SpA is an umbrella term for rheumatic diseases
marked by axial and/or peripheral arthritis. As they
are associated with enthesitis, dactylitis, and potential
extra-articular manifestations, several subtypes are
distinguished.
Ankylosing spondylitis (AS)
Unequivocally acute anterior uveitis (Fig. 2) is con-
sidered to be the most frequent ocular manifestation of
AS since its prevalence is at least 30% of cases with a
frequency peak of 33.4% [24]. AS plays an important
role in the etiology of uveitis since the analysis of the
data of 1916 uveitic patients found AS to be the second
most frequent cause of uveitis with 16.8%, followed
by HLA-B27-positivity, representing 15.4% of
patients [25].
Since AS can affect both the anterior and the
posterior segments of the eye, diversified manifesta-
tions can occur, such as posterior synechiae, cataracts,
elevated intraocular pressure with or without glau-
coma, keratic precipitates, macular edema, and
hypopyon in 5–50% of patients [25]. In a study carried
out among HLA-B27-associated uveitic patients, the
most frequent involvement was diffuse vitritis
(93.1%) followed by papillitis (82.7%). Cystoid
macular edema (37.9%) and epiretinal membrane
(17.2%) along with retinal vasculitis (24.1%) also
appeared among them. The fact that 32% of patients
needed systemic immunosuppressive therapy for their
inflammation is to be taken into consideration [26].
Reactive arthritis (ReA)
ReA is characterized by additive or migratory
oligoarthritis, which is associated with extra-articular
symptoms that distinctively follow a gastrointestinal
or urogenital infection by a minimum of 1 to a
maximum of 3–6 weeks. The first case of ReA
reported in 1918 was a 16-year-old young male with
the classical triad of arthritis, urethritis, and conjunc-
tivitis followed by iritis and keratitis [27].
Surveying clinical data of 25 patients with ReA
uveitis (84%), scleritis (3%), and conjunctivitis (2%)
were found as ocular signs at the time of diagnosis, but
during the follow-up period ocular complications
altered as the leading manifestation was conjunctivitis
(96%), followed by anterior uveitis (92%). The fact
that should be accentuated is that not only anterior
Fig. 2 Chronic anterior uveitis with dilated conjunctival blood
vessels and deformed pupil due to anterior synechiae
123
Int Ophthalmol
segment inflammations such as keratitis (64%) and
scleritis (28%) were seen, but also posterior segment
inflammations such as posterior uveitis (64%), inter-
mediate uveitis (40%), papillitis (16%) too; moreover,
other anomalies, namely cystoid macular edema
(28%), cataract (56%), and glaucoma (16%), were
also found in a relevant rate [28].
Enteropathic arthritis
Enteropathic arthritis predominantly occurs on the
basis of an IBD (Crohn’s disease (CD) or ulcerative
colitis (UC)). Within the extra-intestinal complica-
tions of IBD, the frequency of ophthalmic complica-
tions (OC) features 2–6%, and CD patients are more
intensely exposed [29]. Episcleritis and anterior
uveitis are well-known extra-intestinal manifestations
of CD. Posterior scleritis is an extremely rare condi-
tion that may be idiopathic or related to collagen
vascular diseases [30].
Psoriatic arthritis (PsA)
Historically, an ocular manifestation in PsA was first
reported by Morax in 1893 in a 37-year-old male
patient with arthritis and psoriasis who developed
unilateral iritis and hypopyon [31]. Lambert and
Wright investigated 112 PsA patients and found that
31.25% of them had ocular changes. The leading
alteration was conjunctivitis (19.6%) followed by iritis
(7.1%), DED (2.7%), and episcleritis (1.8%) [32]. The
association of posterior scleritis with PsA was demon-
strated for the first time by Altan-Yaycioglu and co-
workers with the case of a 74-year-old female patient.
Oral azathioprine and prednisone therapy was initi-
ated, and it resolved her problem, although 4 months
later her scleritis recurred [33].
Drawing a comparison between ocular manifesta-
tions of psoriasis and PsA, the latter group has more
ocular complications than the previous one [34].
Undifferentiated spondyloarthritis
Up to 40–82% of acute anterior uveitis (AAU) is
associated with the HLA-B27 allele [35], which is
strongly connected to SpAs. A large, observational
case series study including 175 patients with HLA-
B27-associated AAU was investigated, and 21 (12%)
of them were diagnosed with undifferentiated spondy-
loarthropathies [36].
Juvenile onset spondyloarthritis
This term is used for SpAs under 17 years of age. A
remarkable case series study was described by Menkes
et al.; 31 of their 35 cases were boys, and during the
course of the study typical as well as possible ASs
were investigated, and five patients had ocular man-
ifestations [37].
Scleroderma or systemic sclerosis (SSc)
Scleroderma or systemic sclerosis (SSc) is a chronic,
systemic, connective tissue disease of unknown origin
traditionally divided into two subgroups: limited
cutaneous (lcSS) and diffuse cutaneous (dcSS) types.
Eyelid involvement
Various clinical signs can occur: eyelid stiffness,
eversion, lagophthalmos, blepharophimosis, loss of
eyelashes, and sometimes eyebrows, i.e., ciliary
madarosis which is mainly present in dcSSc [38]. As
for vasculopathy, it is manifested in the form of
telangiectasia and it is perceived in 17–21% of
patients, typically together with telangiectasia located
elsewhere on the face (Fig. 3) [39].
Fig. 3 Blepharophimosis, ciliary madarosis (a) and telangiec-
tasia (b) on the eyelids of SSc patients
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Conjunctiva/episclera
Being a richly vascularized tissue, conjunctiva is
highly affected by vasculopathy, which is realized as
obliteration of the microvasculature, compensatory
angiogenesis, telangiectasia, intravascular sludging,
or loss of vessels [40].
DED
DED is thought to be the most common ocular
manifestation of SSc followed by eyelid skin defor-
mations [41]. S¸ahin and co-workers declared that
beyond the fact that corneas of SSc patients are thinner
compared with those of normal controls, coexistence
of DED induces an additional decrease in corneal
thickness [42]. SSc patients only realize their DED
symptoms after a longer period of the disease as
proved by a study examining objective signs and
subjective symptoms of DED in SSc patients [43].
Iris
One of the most characteristic features in iris is
transillumination, i.e., atrophy, which is an abnormal-
ity of the iris epithelium and identified as a conse-
quence of imperfection of the epithelium [41]. Two
factors, the iris being a part of the uveal tract plus
widespread small vessel vasculopathy being one of the
main pathomechanisms in SSc, account for the
presence of manifestations affecting the iris [38].
Retina/choroid
The first case report about retinal changes in SSc was
published in 1953 by Agatston detecting retinal
cystoid bodies in an SSc patient [44]. Other hetero-
geneous retinal abnormalities have already been
observed for several decades like soft and hard
exudates, neuroretinal edema, hemorrhages, fibrinoid
changes, and lipid deposits [45]. Most of them are
described in dcSSc, and as advanced or difficult cases
it could be problematic to distinguish them from signs
of hypertensive retinopathy.
Polymyalgia rheumatica (PMR)
Polymyalgia rheumatica (PMR) is an inflammatory
condition of unknown origin characterized by pain or
stiffness in the cervical region, shoulders, and upper
arms mostly, but it may occur all over the body.
The first mention of a possible association between
PMR and an ocular manifestation, namely scleritis,
was by Tuft and Watson who reviewed the clinical
features of 290 patients with scleral inflammation and
found 2 diffuse anterior scleritis cases associated with
PMR [46]. The highest number of patients with ocular
involvements of PMR was described by Faez et al.
who processed 7 cases with scleritis or uveitis. What
deserves attention in their work is that 2 out of 7 cases
were panuveitis and in one patient uveitis developed
2 months before PMR was actually diagnosed [47].
One case highlights the challenging diagnostic nature
of Wegener’s granulomatosis (WG) that may evolve
on a background of PMR, and for this reason
undifferentiated ocular inflammatory syndromes
should raise the suspicion of WG [48].
Conclusions
Because of its anatomical structure and privileged
immune system, the eye is susceptible to immunologic
disorders, vascular irregularities, and different kinds
of inflammations. It could be a responsive marker for
the onset or aggravation of an immune reactivation in
many rheumatic diseases; moreover, ocular findings
can precede the diagnosis of the underlying rheumatic
disease. With this end in view, one should not
extenuate extra-articular manifestations. By recogniz-
ing ocular manifestations of systemic rheumatic
diseases, it might be possible to avoid or at least delay
many long-term sequelae.
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